AR100910A1 - ORAL DOSAGE FORM OF SUSTAINED RELEASE CONTAINING MORPHINE AND NALOXONE - Google Patents
ORAL DOSAGE FORM OF SUSTAINED RELEASE CONTAINING MORPHINE AND NALOXONEInfo
- Publication number
- AR100910A1 AR100910A1 ARP150101963A ARP150101963A AR100910A1 AR 100910 A1 AR100910 A1 AR 100910A1 AR P150101963 A ARP150101963 A AR P150101963A AR P150101963 A ARP150101963 A AR P150101963A AR 100910 A1 AR100910 A1 AR 100910A1
- Authority
- AR
- Argentina
- Prior art keywords
- naloxone
- dosage form
- sustained release
- oral dosage
- release containing
- Prior art date
Links
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title abstract 6
- 229960005181 morphine Drugs 0.000 title abstract 3
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title abstract 3
- 229960004127 naloxone Drugs 0.000 title abstract 3
- 239000006186 oral dosage form Substances 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Forma de dosificación oral con liberación sostenida que comprende morfina o una sal fisiológicamente admisible de la misma y naloxona o una sal fisiológicamente admisible de la misma en la terapia de substitución oral para dependientes de opiáceos, la forma de dosificación contiene de 0,5 a 2 mg de naloxona por 100 mg de morfina.Oral dosage form with sustained release comprising morphine or a physiologically acceptable salt thereof and naloxone or a physiologically acceptable salt thereof in oral substitution therapy for opioid dependent, the dosage form contains from 0.5 to 2 mg of naloxone per 100 mg of morphine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP150101963A AR100910A1 (en) | 2015-06-18 | 2015-06-18 | ORAL DOSAGE FORM OF SUSTAINED RELEASE CONTAINING MORPHINE AND NALOXONE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP150101963A AR100910A1 (en) | 2015-06-18 | 2015-06-18 | ORAL DOSAGE FORM OF SUSTAINED RELEASE CONTAINING MORPHINE AND NALOXONE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100910A1 true AR100910A1 (en) | 2016-11-09 |
Family
ID=58699919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101963A AR100910A1 (en) | 2015-06-18 | 2015-06-18 | ORAL DOSAGE FORM OF SUSTAINED RELEASE CONTAINING MORPHINE AND NALOXONE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR100910A1 (en) |
-
2015
- 2015-06-18 AR ARP150101963A patent/AR100910A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000306A (en) | PHARMACEUTICAL FORMULATIONS CONTAINING TENOFOVIR AND EMTRICITABINE | |
| PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
| CL2015003690A1 (en) | Use of pridopidine or a salt thereof to prepare a medication useful in the treatment of huntington's disease. | |
| MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| CL2015002733A1 (en) | Pharmaceutical composition of s-ketamine hydrochloride. | |
| BR112015020466A8 (en) | cdc7 inhibitors, their uses, and pharmaceutical composition | |
| CR20180253A (en) | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS | |
| UA115811C2 (en) | A STABLE SOLUTION OF ASSOCIATED Baclofen, Sorbitol and Naltrexone for Oral Use | |
| MX2016002580A (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases. | |
| MX347105B (en) | Pharmaceutical compositions comprising hydromorphone and naloxone. | |
| CY1122387T1 (en) | DUAL USE TABLETS OF ORAL PHARMACEUTICAL COMPOSITION OF SULFATE SALTS AND METHODS OF USING THEREOF | |
| CR20150266A (en) | MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB | |
| CL2013003198A1 (en) | Use of volasertib, a salt or a hydrate thereof to prepare a drug useful in the treatment of solid malignancies that include advanced and metastatic solid malignancies. | |
| PH12016500666A1 (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| MX2016006087A (en) | Rapidly disintegrating formulations and methods of use. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| AR094241A1 (en) | CICLESONIDE FOR THE TREATMENT OF RESPIRATORY ROAD DISEASE IN HORSES | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| CL2016000182A1 (en) | Stable anti-tuberculosis pharmaceutical composition in a form of a coated tablet comprising isoniazid granules and rifapentin granules and their preparation process | |
| PH12015501294A1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| AR100910A1 (en) | ORAL DOSAGE FORM OF SUSTAINED RELEASE CONTAINING MORPHINE AND NALOXONE | |
| CR20170601A (en) | PHARMACEUTICAL FORMULATIONS THAT INCLUDE TENOFOVIR AND EMTRICITABINA | |
| PH12017500346A1 (en) | Film coated tablet for the treatment of acute pain | |
| AR098884A1 (en) | NOTCH ACTIVATION CHANGES IN BREAST CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |